Literature DB >> 9606764

Rheumatic manifestations of parvovirus B19 infection.

S J Naides1.   

Abstract

Human parvovirus B19 is an emerging DNA virus. B19 infection is common and widespread. Major manifestations of B19 infection are transient aplastic crisis, erythema infectiosum, hydrops fetalis, acute and chronic rheumatoid-like arthropathy, and, in the immunocompromised host, chronic or recurrent bone marrow suppression. A number of less common manifestations of B19 infection include various rash illnesses, neuropathies, and acute fulminant liver failure. Of rheumatologic interest, B19 infection must be differentiated from early presentation of more classic erosive rheumatoid arthritis and, in some cases, systemic lupus erythematosus. It is unlikely that B19 plays a role in classic erosive rheumatoid arthritis, but understanding pathogenesis of B19 arthropathy may provide insights into the mechanisms by which rheumatoid arthritis develops. Evidence for persistence of B19 infection suggests that human parvovirus B19 infection may serve as a model for the study of virus-host interactions and the role of viruses in the pathogenesis of rheumatic diseases.

Entities:  

Mesh:

Year:  1998        PMID: 9606764     DOI: 10.1016/s0889-857x(05)70014-4

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  17 in total

Review 1.  Mechanisms of viral pathogenesis in rheumatic disease.

Authors:  A Perl
Journal:  Ann Rheum Dis       Date:  1999-08       Impact factor: 19.103

Review 2.  Parvovirus B19 infection in human pregnancy.

Authors:  R F Lamont; J D Sobel; E Vaisbuch; J P Kusanovic; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero
Journal:  BJOG       Date:  2010-10-13       Impact factor: 6.531

Review 3.  Chronic Chikungunya Arthritis and Rheumatoid Arthritis: What They Have in Common.

Authors:  J Kennedy Amaral; Joshua B Bilsborrow; Robert T Schoen
Journal:  Am J Med       Date:  2019-11-06       Impact factor: 4.965

Review 4.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

5.  The role of human xanthine oxidoreductase (HXOR), anti-HXOR antibodies, and microorganisms in synovial fluid of patients with joint inflammation.

Authors:  Najah Al-Muhtaseb; Elham Al-Kaissi; Abdul Jalil Thawaini; Zuhair Muhi Eldeen; Sabah Al-Muhtaseb; Badiee Al-Saleh
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

Review 6.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

7.  Parvovirus B19 induced hepatic failure in an adult requiring liver transplantation.

Authors:  Darin S Krygier; Urs P Steinbrecher; Martin Petric; Siegfried R Erb; Stephen W Chung; Charles H Scudamore; Andrzej K Buczkowski; Eric M Yoshida
Journal:  World J Gastroenterol       Date:  2009-08-28       Impact factor: 5.742

Review 8.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

9.  A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a).

Authors:  Ellen Jo Baron; J Michael Miller; Melvin P Weinstein; Sandra S Richter; Peter H Gilligan; Richard B Thomson; Paul Bourbeau; Karen C Carroll; Sue C Kehl; W Michael Dunne; Barbara Robinson-Dunn; Joseph D Schwartzman; Kimberle C Chapin; James W Snyder; Betty A Forbes; Robin Patel; Jon E Rosenblatt; Bobbi S Pritt
Journal:  Clin Infect Dis       Date:  2013-07-10       Impact factor: 9.079

Review 10.  Systemic lupus erythematosus and parvovirus B-19: casual coincidence or causative culprit?

Authors:  Marianne C Severin; Yair Levy; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.